Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
- Sponsor
- Sun Yat-sen University
- Study ID
- NCT06373744
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- cyclophosphamide , methotrexate , vinorelbine ,capecitabine — DRUGThe drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
Study Details
The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is: How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy.
Key Dates
- Start date
- Jan 1, 2023
- Status verified
- Apr 2024
- Primary completion
- Jan 1, 2024
- Completion
- Jan 1, 2024
Study Design
- Enrollment
- 597 participants (actual)
Arms
- Arm: metronomic chemotherapyPatients with advanced breast cancer who received metronomic chemotherapy.
Primary Outcome Measure
Progression free survival [ Time Frame: Baseline up to approximately 20 months ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland